Insider Selling: Bioventus (NASDAQ:BVS) Director Sells $105,480.00 in Stock

Bioventus Inc. (NASDAQ:BVS) Director Michelle Mcmurry-Heath sold 12,000 shares of Bioventus stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $8.79, for a total transaction of $105,480.00. Following the completion of the transaction, the director directly owned 44,997 shares in the company, valued at $395,523.63. The trade was a 21.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Bioventus Stock Up 0.2%

Shares of NASDAQ:BVS opened at $8.62 on Monday. Bioventus Inc. has a 1-year low of $5.81 and a 1-year high of $10.13. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.70 and a quick ratio of 1.19. The stock has a market cap of $716.75 million, a P/E ratio of 26.12 and a beta of 0.78. The firm has a fifty day moving average price of $8.25 and a 200 day moving average price of $7.55.

Bioventus (NASDAQ:BVS) last posted its quarterly earnings data on Thursday, March 5th. The company reported $0.24 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.02. Bioventus had a net margin of 4.00% and a return on equity of 28.88%. The company had revenue of $157.90 million for the quarter. Bioventus has set its FY 2026 guidance at 0.730-0.770 EPS.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Bioventus by 7.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock valued at $211,000 after purchasing an additional 1,538 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Bioventus by 19.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 162,412 shares of the company’s stock worth $1,486,000 after buying an additional 26,103 shares in the last quarter. Fox Run Management L.L.C. acquired a new stake in shares of Bioventus in the 2nd quarter valued at approximately $72,000. Los Angeles Capital Management LLC lifted its holdings in shares of Bioventus by 23.2% in the 2nd quarter. Los Angeles Capital Management LLC now owns 121,835 shares of the company’s stock valued at $807,000 after buying an additional 22,915 shares during the period. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in shares of Bioventus in the second quarter valued at approximately $449,000. 62.94% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

BVS has been the subject of several analyst reports. Barrington Research upped their price objective on Bioventus from $13.00 to $14.00 and gave the company an “outperform” rating in a research note on Friday, March 6th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Bioventus in a research note on Monday, December 29th. Craig Hallum boosted their target price on Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a report on Friday, March 6th. Finally, Cantor Fitzgerald upgraded Bioventus to a “strong-buy” rating in a research note on Wednesday, March 4th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $14.25.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.